Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × dabrafenib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 3 Thyroid Carcinoma, Anaplastic 2 Neoplasms 2 Glioma 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Solid Tumor 1 Skin Neoplasms 1 Sexual Dysfunction, Physiological 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Recurrence 1 Rare Malignant Neoplasm 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Locally Advanced Thyroid Gland Carcinoma 1 Hematologic Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Craniopharyngioma 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Ameloblastoma 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 14 Cytarabine 12 fludarabine 11 Azacitidine 10 Gemcitabine 9 pomalidomide 7 Rituximab 7 Carboplatin 7 selinexor 6 glofitamab 6 Temozolomide 6 Lenalidomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 Paclitaxel 5 Oxaliplatin 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Nivolumab 4 Decitabine 4 Cladribine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡